Mirova US LLC Has $133.94 Million Holdings in Edwards Lifesciences Co. (NYSE:EW)

Mirova US LLC reduced its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 2.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,809,222 shares of the medical research company’s stock after selling 53,910 shares during the quarter. Edwards Lifesciences accounts for approximately 1.6% of Mirova US LLC’s holdings, making the stock its 25th biggest position. Mirova US LLC owned 0.31% of Edwards Lifesciences worth $133,937,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. FSA Wealth Management LLC acquired a new position in Edwards Lifesciences during the 3rd quarter valued at $30,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $30,000. Prospera Private Wealth LLC acquired a new stake in shares of Edwards Lifesciences during the 3rd quarter worth about $32,000. Avior Wealth Management LLC grew its holdings in Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after acquiring an additional 308 shares during the last quarter. Finally, Roble Belko & Company Inc bought a new stake in Edwards Lifesciences during the 4th quarter worth about $46,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Edwards Lifesciences

In related news, Director Steven R. Loranger sold 5,739 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $76.42, for a total value of $438,574.38. Following the transaction, the director now owns 60,372 shares in the company, valued at approximately $4,613,628.24. This trade represents a 8.68 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 400 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $69.48, for a total transaction of $27,792.00. Following the sale, the vice president now owns 22,588 shares in the company, valued at $1,569,414.24. This represents a 1.74 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 51,303 shares of company stock valued at $3,715,776. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of EW stock opened at $70.67 on Tuesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The firm’s 50-day moving average is $71.68 and its two-hundred day moving average is $70.34. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a market capitalization of $41.55 billion, a PE ratio of 10.14, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Wolfe Research downgraded shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. Evercore ISI reduced their target price on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a research report on Wednesday, February 12th. Canaccord Genuity Group boosted their target price on Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a research note on Thursday, February 13th. Truist Financial reaffirmed a “hold” rating and issued a $78.00 price objective (up previously from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Finally, Morgan Stanley upped their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat.com, Edwards Lifesciences presently has an average rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.